Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber

NCT00430157 | Completed Phase 2

• 1 other identifier: IPR107498
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

This study is in patients with seasonal allergic rhinitis (SAR) and will compare the effect versus placebo of repeat doses of intranasal GSK256066 using the Vienna Challenge Chamber. GSK256066 is a potent and highly selective phosphodiesterase-4 (PDE4) inhibitor, currently in development by GSK for the treatment of allergic rhinitis, asthma and COPD. Subjects will be selected on the basis that they display a defined moderate response to the pre-determined dose used. This study aims to explore the actions of repeat doses of intranasal GSK256066 in patients with Seasonal Allergic Rhinitis in the Vienna Challenge Chamber compared to placebo. 12-lead ECG, vital signs and adverse event enquiries will be made throughout the study. Nasal examination, symptom scores (TNSS), nasal lavage, nasal scrape and allergen challenge assessments will also be performed at various time points throughout the study.

Conditions

Rhinitis, Allergic, Seasonal; Seasonal Allergic Rhinitis

Keywords

Vienna Challenge Chamber; Seasonal Allergic Rhinitis; Inflammation

Outcome Measures

Primary Outcomes (1)

• Weighted mean total nasal symptom score (TNSS) (sneeze, itch, rhinorrhoea and obstruction)

  1-4h post-dose period spent in the Vienna Challenge Chamber on Day 7

Secondary Outcomes (1)

• Weighted mean total nasal symptom score (TNSS) (sneeze, itch, rhinorrhoea and obstruction)

  1-4h post morning dose period spent in the Vienna Challenge Chamber on Day 2.

Interventions

GSK256066 DRUG

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• The subject is healthy.
• They are aged 18 to 50 years inclusive.
• Body mass index less than 29.0 kg/m² with weight range of 55.0kg (females 50kg) to 95.0kg inclusive.
• They have a history of seasonal allergic rhinitis
• They exhibit a moderate response to 1500 grass pollen grains/m3 after 2h in the Vienna Challenge Chamber,
• They have a positive skin prick test for grass pollen at or within the 12 months preceding the screening visit.
• They have a positive RAST for grass pollen at or within the 12 months preceding the screening visit.
• They are current non-smokers who have not used any tobacco products in the 6 months preceding the screening visit
• They must have a baseline FEV1\>80% predicted and a baseline FEV1 (maximum recorded value)/ FVC (associated value)\>70% predicted.

You may not qualify if:

• Pregnant or nursing females.
• Women of childbearing potential who are unwilling or unable to use an appropriate method of contraception.
• any structural nasal abnormalities or nasal polyposis, a history of frequent nosebleeds, recent nasal surgery or recent (within 2 weeks) or ongoing upper respiratory tract infection.
• The subject is likely to be unable to abstain from salbutamol use for 8 hours before a challenge
• The subject has a history of drug or other allergy
• The subject is concurrently participating in another clinical study in the past 3 months
• A supine blood pressure that is persistently higher than 140/90 millimetres of mercury (mmHg) at screening
• A supine mean heart rate outside the range 40-90 beats per minute (bpm) at screening.
• The subject has donated a unit of blood within the previous 3 months.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Vienna, A-1150, Austria

Location

MeSH Terms

Conditions

Rhinitis, Allergic, Seasonal; Inflammation

Interventions

6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide

Condition Hierarchy (Ancestors)

Rhinitis, Allergic; Rhinitis; Nose Diseases; Respiratory Tract Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 30, 2007
• First Posted: February 1, 2007
• Study Start: January 1, 2007
• Last Updated: June 4, 2012

Record last verified: 2011-02

Locations

AU (1)